G

Genus

Global animal genetics and breeding technology

Technical Services Senior Specialist - Applied Female Reproduction

Full-TimeDeadline 10/4/27
$88k - $110k
Mid
Bachelor's, Master's
Remote in USA
RemoteIdeally based in the Midwestern US; approximately 50% travel within North America, potentially more as business needs require.
Biology & Biotech

About the job

Requirements
  • A bachelor's degree in Agriculture, Animal Science, or a related discipline.
  • At least 3 years of demonstrated swine production experience, with the ability to enhance production performance and efficiency.
  • Ability to evaluate production systems and develop targeted intervention strategies that improve processes, productivity, and financial outcomes.
  • Ability to assimilate, analyze, and clearly communicate technical information, including preparing technical papers and materials to support sales efforts.
  • Ability to work independently and manage travel requirements.
  • Willingness to travel approximately 50% within North America, with travel potentially increasing based on business needs.
Responsibilities
  • Deliver post-sale services at customer sites, monitor agreements on intervention actions when necessary, and oversee on-farm implementation strategies to achieve expected genetic-program results.
  • Assess farm conditions, identify performance opportunities, and provide practical, production-focused recommendations, including advice on non-genetic factors related to applied female reproduction.
  • Apply best practices and knowledge to help customers improve profitability and return on investment with the company's genetics.
  • Communicate and support implementation of the company's health, genetic, management, and nutrition guidelines.
  • Support customer and multiplication partner farms to optimize performance at mature and start-up farms.
  • Identify and manage customer production-improvement projects, including increasing gilt selection rates, improving feeding-management practices, and increasing weaned-pig output, quality, and efficiency.
  • Participate in applied field research trials or customer data-analysis projects to improve the company's production guidelines.
  • Work with a team to improve animal-husbandry practices across production phases, train staff in successful implementation and standardization, review programs after implementation, ensure targets and goals are met, and partner on collaborative technical projects.
  • Develop monthly reports focused on key initiatives, project metrics, and performance.
  • Maintain appropriate standards of conduct in dealings with customers, employees, and allied industry, including social, professional, ethical, and animal-well-being obligations.
  • Explain difficult or sensitive information, build agreements with others, exercise judgment using analytical thought, and identify innovative solutions.
  • Communicate difficult concepts and negotiate to gain adoption of a different point of view.
  • Use specialized knowledge and expertise to lead teams and projects with moderate risks and resource requirements.
Desired Qualifications
  • A master's degree in agriculture, animal sciences, or a related field.
  • Spanish language proficiency.

About the company

Genus is a global animal-genetics company focused on improving cattle and pig performance through breeding and genetic technologies. It operates two main units, ABS Global for bovine genetics and PIC for porcine genetics, offering breeding animals, reproduction services, and gene-editing and next-generation breeding tools. Its products work by combining genetics, reproductive biology, and data-driven selection to produce healthier herds, higher-quality food, and more efficient production. Genus differentiates itself through its global scale (operations in 30 countries and distribution to over 50 markets), its specialized units for cattle and pigs, and its integration of science with practical farming solutions. Its goal is to sustainably nourish the world by improving animal health, food quality, and the resilience of the global food system, while delivering value to customers and upholding ethical, collaborative values.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Basingstoke, United Kingdom

Founded

1933

Get referred to Genus

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Genus said 14 July 2026 FY26 results should beat consensus and cut leverage.
  • The Chinese porcine joint venture delivered about £111 million cash in FY26.
  • ABS posted double-digit profit growth in FY26, helped by the Value Acceleration Programme.

What critics are saying

  • North American PIC volumes weakened in FY26 from customer disease challenges.
  • Genus still depends on further approvals before selling PRRS-resistant pigs in Canada.
  • If EU and U.S. adoption stalls, PRRS-resistant pigs stay a stranded platform.

What makes Genus unique

  • PIC’s PRRS-resistant pigs won Canada approval on 23 January 2026.
  • Genus monetizes elite genetics through recurring royalties, not commodity livestock sales.
  • ABS and PIC combine bovine and porcine genetics across 100-plus countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Parental Leave
  • Employee Stock Purchase Plan
  • Paid Holidays
  • Paid Vacation

Company News

Associated Press
Jan 23rd, 2026
Canada approves PRRSV-resistant pigs for food and feed to cut farm losses and antibiotic use

Canada has approved genetically engineered pigs resistant to porcine reproductive and respiratory syndrome viruses for use in food and feed. Health Canada and the Canadian Food Inspection Agency completed independent safety assessments following applications from Genus PLC and PIC Canada, concluding the pigs are as safe and nutritious as conventional pork. The approval addresses PRRSV, one of the most devastating virus classes affecting farmed pigs, which causes severe symptoms including breathing problems, fever and stillborn piglets. There are currently no effective treatments available. Genus PLC's PRRSV-resistant pigs are already approved in the US, Brazil, Colombia and the Dominican Republic. However, the company will not sell these pigs in Canada until receiving regulatory authorisation in other key markets. Canada's swine industry generated over $6.3 billion in farm cash receipts in 2024.

TipRanks
Oct 21st, 2024
Genus plc CFO to Retire, Successor Search Underway

Genus plc, a global leader in animal genetics, has announced the upcoming retirement of its Chief Financial Officer, Alison Henriksen, who will leave her role in July 2025 after five years with the company.

PharmiWeb
Sep 7th, 2023
Genus Plc Preliminary Results For The Year Ended 30 June 2023

SOLID PERFORMANCE AND GOOD STRATEGIC PROGRESSWEBCAST AVAILABLE AT 7:01AM GMT, 2.01 ESTLONDON--(BUSINESS WIRE)--Genus (LSE:GNS), a leading global animal genetics company, today announces its preliminary results for the year ended 30 June 2023. The full report has been made available on the investors section of the Genus plc website. The Company will discuss its corporate, operational and financial highlights in a pre-recorded webcast at 7:01 AM GMT, 2.01 EST.Commenting on the performance and outlook, Jorgen Kokke, Chief Executive Officer, said:“The Group achieved a strong operational performance despite ongoing challenging market conditions for producers in several important markets. Revenues grew in all regions and both PIC and ABS delivered profit growth. This also enabled us to deliver record adjusted EBITDA and good cashflow for the Group. Growth in R&D investments, primarily due to the strategically important gene editing work and expansion of PIC’s elite farms, as well as higher interest costs, resulted in adjusted profit before tax consistent with the prior year.“PIC’s performance was particularly impressive, achieving a record adjusted operating profit for the year

MarketWatch
Apr 3rd, 2023
Genus Names Jorgen Kokke as Chief Executive Officer Designate

Genus PLC said Monday that it has appointed Jorgen Kokke as chief executive officer designate, effective from May 2.

PharmiWeb
Sep 8th, 2022
Genus Plc Reports Preliminary Results For The Year Ended 30 June 2022

Continued Strategic Progress in Challenging Markets. Webcast Available at 7:01AM BST, 2.01 EDT